NSR Nestor Health.

TIDMNSR

RNS Number : 8786W

Nestor Healthcare Group PLC

26 November 2010

26 November 2010

Nestor Healthcare Group PLC ("Nestor" or the "Company")

Revised approach

Following the announcement released by the Company on 7 October 2010 in relation to a revised indicative approach from Acromas Holdings Limited ("Acromas"), the Directors of Nestor (the "Board") confirm that they have received a further revised indicative approach from Acromas of 110 pence per ordinary share in cash. Under the terms of the revised indicative approach Nestor shareholders would also receive a second interim dividend for the year ending 31 December 2010 of 2.5 pence per ordinary share.

The Board confirms that it continues in discussions with Acromas, however no formal offer has been received and there can be no certainty that a formal offer will be made, nor as to the terms on which any offer might be made.

This announcement has been made with the agreement of Acromas. Further announcements will be made as appropriate.

For further information please contact: Investec Investment Banking Tel: +44 (20) 7597 5970

Martin Smith

Cara Griffiths

Alex Thomson

Citigate Dewe Rogerson Tel: +44 (20) 7638 9571

Toby Mountford

Ged Brumby

Investec Investment Banking, a division of Investec Bank plc, which is authorised and regulated by the Financial Services Authority in the United Kingdom, is acting exclusively for Nestor and no one else in connection with matters described in this announcement and will not be responsible to anyone other than Nestor for providing the protections afforded to clients of Investec Investment Banking nor for providing advice in relation to matters described in this announcement.

Under Rule 8.3(a) of the Code, any person who is interested in 1 per cent. or more of any class of relevant securities of an offeree company or of any paper offeror (being any offeror other than an offeror in respect of which it has been announced that its offer is, or is likely to be, solely in cash) must make an Opening Position Disclosure following the commencement of the offer period and, if later, following the announcement in which any paper offeror is first identified.

An Opening Position Disclosure must contain details of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror(s). An Opening Position Disclosure by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm (London time) on the 10th business day following the commencement of the offer period and, if appropriate, by no later than 3.30 pm (London time) on the 10th business day following the announcement in which any paper offeror is first identified. Relevant persons who deal in the relevant securities of the offeree company or of a paper offeror prior to the deadline for making an Opening Position Disclosure must instead make a Dealing Disclosure.

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1 per cent. or more of any class of relevant securities of the offeree company or of any paper offeror must make a Dealing Disclosure if the person deals in any relevant securities of the offeree company or of any paper offeror. A Dealing Disclosure must contain details of the dealing concerned and of the person's interests and short positions in, and rights to subscribe for, any relevant securities of each of (i) the offeree company and (ii) any paper offeror, save to the extent that these details have previously been disclosed under Rule 8. A Dealing Disclosure by a person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm (London time) on the business day following the date of the relevant dealing.

If two or more persons act together pursuant to an agreement or understanding, whether formal or informal, to acquire or control an interest in relevant securities of an offeree company or a paper offeror they will be deemed to be a single person for the purpose of Rule 8.3. Opening Position Disclosures must also be made by the offeree company and by any offeror and Dealing Disclosures must also be made by the offeree company, by any offeror and by any persons acting in concert with any of them (see Rules 8.1, 8.2 and 8.4). Details of the offeree and offeror companies in respect of whose relevant securities Opening Position Disclosures and Dealing Disclosures must be made can be found in the Disclosure Table on the Takeover Panel's website at www.thetakeoverpanel.org.uk, including details of the number of relevant securities in issue, when the offer period commenced and when any offeror was first identified. If you are in any doubt as to whether you are required to make an Opening Position Disclosure or a Dealing Disclosure, you should contact the Panel's Market Surveillance Unit on +44 (0)20 7638 0129."

"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the Panel's website. If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, you should consult the Panel.

A copy of this announcement will be available on the Company's website at http://ww1.investorrelations.co.uk/Nestor/announcements/pressreleases/

This information is provided by RNS

The company news service from the London Stock Exchange

END

OUPEAFFKADPEFFF

Nestor Healthcare (LSE:NSR)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025

Nestor Healthcare (LSE:NSR)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025